Dr. Reveals What Really Happened at the FDA Meeting on Peptides

I attended the FDA Pharmacy Compounding Advisory Committee (PCAC) hearing in Washington, D.C. on peptide compounding. What I witnessed changed how I view the FDA process forever. While the committee voted YES to recommend 6 out of 7 peptides—including BPC-157, TB-500, KPV, Semax, Epitalon, and MOTS-c—the agency's preparation, lack of data review, and arguments left many doctors in the room stunned. In this video, I break down what happened behind closed doors, why the panel voted against the FDA’s recommendations, and what this decision means for compound pharmacies, patient safety, and the future of bioidentical peptides. Physicians and Prescribers - Don't get left behind. Prepare yourself for the waves of patients asking for peptides : https://courses.drafroese.com/